varenicline	placebo	continuous abstienence at 24 week follow up	-1	-1	Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001) and through 24 weeks follow-up (Weeks 9?24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6?7.5; p < .0001).
varenicline	placebo	continuous abstienence at 24 week follow up	-1	-1	Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9�??12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7�??9.4; p < .0001) and through 24 weeks follow-up (Weeks 9�??24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6�??7.5; p < .0001).
varenicline	placebo	continuous abstienence at week 12	-1	-1	Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001) and through 24 weeks follow-up (Weeks 9?24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6?7.5; p < .0001).
varenicline	placebo	frequency of quit events by day 35	19470	19619	By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062). 
varenicline	placebo	continuous abstienence at week 12	-1	-1	Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9�??12: 53.1% vs. 19.3%;
varenicline	placebo	time to make first quit attempt	19619	19803	Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074), with a median of 17 versus 24 days, respectively (Figure 2).
varenicline	placebo	continuous abstienence at 24 week follow up	1152	1426	Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7–9.4; p < .0001) and through 24 weeks follow-up (Weeks 9–24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6–7.5; p < .0001)
varenicline	placebo	continuous abstienence at week 12	1152	1426	Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7–9.4; p < .0001) and through 24 weeks follow-up (Weeks 9–24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6–7.5; p < .0001)
varenicline	placebo	frequency of quit events by day 35	19470	19618	By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062).
varenicline	placebo	continuous abstienence at week 12	1152	1329	Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7–9.4; p < .0001)
